You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Merck
Moodys
McKesson
AstraZeneca

Last Updated: May 31, 2020

DrugPatentWatch Database Preview

Bausch And Lomb Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Bausch And Lomb
International Patents:180
US Patents:22
Tradenames:66
Ingredients:53
NDAs:77
Patent Litigation for Bausch And Lomb: See patent lawsuits for Bausch And Lomb

Drugs and US Patents for Bausch And Lomb

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE polymyxin b sulfate; trimethoprim sulfate SOLUTION/DROPS;OPHTHALMIC 064120-001 Feb 14, 1997 AT RX No No   Start Trial   Start Trial
Bausch And Lomb OFLOXACIN ofloxacin SOLUTION/DROPS;OPHTHALMIC 076622-001 May 14, 2004 AT RX No No   Start Trial   Start Trial
Bausch And Lomb HYDROCORTISONE AND ACETIC ACID acetic acid, glacial; hydrocortisone SOLUTION/DROPS;OTIC 040097-001 Oct 31, 1994 DISCN No No   Start Trial   Start Trial
Bausch And Lomb ERYTHROMYCIN erythromycin OINTMENT;OPHTHALMIC 064067-001 Jul 29, 1994 AT RX No No   Start Trial   Start Trial
Bausch And Lomb MINOXIDIL (FOR MEN) minoxidil SOLUTION;TOPICAL 074643-001 Apr 9, 1996 DISCN No No   Start Trial   Start Trial
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 RX Yes Yes 8,415,342   Start Trial   Start Trial
Bausch And Lomb TOBRAMYCIN AND DEXAMETHASONE dexamethasone; tobramycin SUSPENSION/DROPS;OPHTHALMIC 064134-001 Oct 27, 1999 AB RX No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Bausch And Lomb

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb LOTEMAX loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 020583-001 Mar 9, 1998 5,540,930*PED   Start Trial
Bausch And Lomb ZYLET loteprednol etabonate; tobramycin SUSPENSION/DROPS;OPHTHALMIC 050804-001 Dec 14, 2004 5,747,061*PED   Start Trial
Bausch And Lomb ALREX loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 020803-001 Mar 9, 1998 4,996,335*PED   Start Trial
Bausch And Lomb RETISERT fluocinolone acetonide IMPLANT;INTRAVITREAL 021737-001 Apr 8, 2005 6,217,895   Start Trial
Bausch And Lomb MIOCHOL-E acetylcholine chloride FOR SOLUTION;OPHTHALMIC 020213-001 Sep 22, 1993 6,261,546   Start Trial
Bausch And Lomb ISTALOL timolol maleate SOLUTION/DROPS;OPHTHALMIC 021516-001 Jun 4, 2004 6,645,963   Start Trial
Bausch And Lomb ALREX loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 020803-001 Mar 9, 1998 5,540,930*PED   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BAUSCH AND LOMB drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Ophthalmic Solution 0.07% ➤ Subscribe 2013-07-26
➤ Subscribe Ophthalmic Solution 0.5% ➤ Subscribe 2012-10-19
➤ Subscribe Ophthalmic Solution 1.5% ➤ Subscribe 2013-09-09

Supplementary Protection Certificates for Bausch And Lomb Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1586316 132011901975261 Italy   Start Trial PRODUCT NAME: BROMFENAC(YELLOX); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/692/001, 20110518
0509752 2000C/001 Belgium   Start Trial PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
0206283 98C0041 Belgium   Start Trial PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606
1280520 122015000021 Germany   Start Trial PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
0694547 C300071 Netherlands   Start Trial PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920
0364417 97C0128 France   Start Trial PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718
0206283 C980016 Netherlands   Start Trial PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Johnson and Johnson
Mallinckrodt
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.